-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

ZYNLONTA®: The First and Only CD19-Directed ADC For 3L DLBCL

Sponsor: ADC Therapeutics
Program: Product Theaters
Monday, December 12, 2022: 8:00 AM-9:00 AM
Hall J - Theater 4 (Ernest N. Morial Convention Center)
Speaker:
Joseph Camardo, MD, ADC Therapeutics, Inc.
Disclosures:
No relevant conflicts of interest to declare.
This presentation is intended for U.S. based registered meeting attendees
See more of: Product Theaters
<< Previous Product Theater | Next Product Theater >>